Nephrology

Filter

Study Uncovers Biomarkers That Could Guide Chronic Kidney Disease Care

August 2025

A large UK study has shown that novel biomarkers reflecting kidney damage, fibrosis, inflammation, and cardiovascular disease can predict kidney failure and all-cause mortality in chronic kidney disease (CKD) with accuracy similar to established clinical risk factors.

Study Uncovers Biomarkers That Could Guide Chronic Kidney Disease Care

A large UK study has shown that novel biomarkers reflecting kidney damage, fibrosis, inflammation, and cardiovascular disease can predict kidney failure and all-cause mortality in chronic kidney disease (CKD) with accuracy similar to established clinical risk factors.

Pilot Trial Explores Sodium Bicarbonate to Preserve Cognition in Chronic Kidney Disease

A pilot randomized trial found sodium bicarbonate therapy modestly improved cognitive scores in older patients with CKD and metabolic acidosis, though these gains weren’t significantly better than placebo.

New Urinary Biomarkers Linked to Slower Progression of Diabetic Kidney Disease

Learn how EGF and UMOD levels may predict diabetic kidney disease progression, offering new tools for clinical risk assessment.

Scientists Discover Parkinson’s May Start in the Kidneys

New research uncovers a potential kidney origin for Parkinson’s disease, challenging the idea that it begins in the brain and revealing a new disease pathway.

ERA 2025: Immune Profiling of Checkpoint Inhibitor-Induced Nephritis Reveals Distinct Subtypes with Prognostic Value

Presented at ERA 2025, this multicentre study identifies three immune subtypes of checkpoint inhibitor–induced nephritis, linking them to clinical outcomes and treatment responses.

ERA 2025: Higher-Dose Canagliflozin Yields Greater Cardiovascular Protection in High-Risk Patients

A post-hoc analysis of the CANVAS trial reveals a dose-dependent cardiovascular benefit with canagliflozin in type 2 diabetes, while kidney protection appears consistent across doses.

ERA 2025: Pegcetacoplan Shows Strong Kidney Benefit in Rare Diseases

Pegcetacoplan demonstrated a significant reduction in proteinuria and signs of kidney damage in patients with C3G or IC-MPGN and nephrotic-range proteinuria, according to VALIANT Phase 3 results.

Immunoglobulin Therapy Slows Kidney Decline in Chronic Rejection, Trial Finds

In a landmark trial, IVIG therapy was shown to slow kidney function decline and tissue damage in patients with chronic active antibody-mediated rejection.

Loading posts...

1 2 3 … 20 Next »